0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Herpes Zoster -Epidemiology Forecast to 2028 9750
Published Date: April 2019
|
Report Code: DELV-Epid-030
Home | Market Reports | Health | Health Conditions | Infectious Diseases
Herpes Zoster Epidemiology Forecast to 2028

Herpes Zoster -Epidemiology Forecast to 2028 9750

Code: DELV-Epid-030
Report
April 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Herpes Zoster - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Herpes Zoster epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Herpes Zoster Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Herpes Zoster in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Herpes Zoster outlook. It also includes the explanation of changing trends of epidemiology outlining the Herpes Zoster scenario.

Herpes Zoster Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Herpes Zoster thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Herpes Zoster explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Herpes Zoster Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Herpes Zoster

Key assessments
• Patient Segmentation in Herpes Zoster
• Herpes Zoster Risk & Burden
• Factors driving growth in a specific Herpes Zoster patient population

1. Report Introduction
2. Herpes Zoster Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Herpes Zoster in 2016
2.2. Patient Share Distribution of Herpes Zoster in 2028
3. Disease Background and Overview: Herpes Zoster
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Herpes Zoster in 7MM
4.3. Total Prevalent/ Incident Patient Population of Herpes Zoster in 7MM – By Countries
5. Epidemiology of Herpes Zoster by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Herpes Zoster
5.1.3. Sub-Type Specific cases of the Herpes Zoster *
5.1.4. Sex- Specific Cases of the Herpes Zoster*
5.1.5. Diagnosed Cases of the Herpes Zoster
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Herpes Zoster
5.4.3. Sub-Type Specific cases of the Herpes Zoster*
5.4.4. Sex- Specific Cases of the Herpes Zoster*
5.4.5. Diagnosed Cases of the Herpes Zoster
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Herpes Zoster
5.5.3. Sub-Type Specific cases of the Herpes Zoster*
5.5.4. Sex- Specific Cases of the Herpes Zoster*
5.5.5. Diagnosed Cases of the Herpes Zoster
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Herpes Zoster
5.6.3. Sub-Type Specific cases of the Herpes Zoster*
5.6.4. Sex- Specific Cases of the Herpes Zoster*
5.6.5. Diagnosed Cases of the Herpes Zoster
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Herpes Zoster
5.7.3. Sub-Type Specific cases of the Herpes Zoster*
5.7.4. Sex- Specific Cases of the Herpes Zoster*
5.7.5. Diagnosed Cases of the Herpes Zoster
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Herpes Zoster
5.8.3. Sub-Type Specific cases of the Herpes Zoster*
5.8.4. Sex- Specific Cases of the Herpes Zoster*
5.8.5. Diagnosed Cases of the Herpes Zoster
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Herpes Zoster
5.9.3. Sub-Type Specific cases of the Herpes Zoster*
5.9.4. Sex- Specific Cases of the Herpes Zoster*
5.9.5. Diagnosed Cases of the Herpes Zoster
6. Unmet Needs of the Herpes Zoster
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables :

Table 1: Total Prevalent/Incident Cases of the Herpes Zoster in 7MM
Table 2: Total Prevalent/Incident Cases of the Herpes Zoster in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Herpes Zoster in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Herpes Zoster in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Herpes Zoster in United States (2016-2028)*
Table 6: Diagnosed Cases of the Herpes Zoster in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Herpes Zoster in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Herpes Zoster in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Herpes Zoster in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Herpes Zoster in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Herpes Zoster in France (2016-2028)
Table 12: Sub-Type Specific cases of the Herpes Zoster in France (2016-2028) *
Table 13: Sex- Specific Cases of the Herpes Zoster in France (2016-2028) *
Table 14: Diagnosed Cases of the Herpes Zoster in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Herpes Zoster in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Herpes Zoster in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Herpes Zoster in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Herpes Zoster in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Herpes Zoster in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Herpes Zoster in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Herpes Zoster in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Herpes Zoster in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Herpes Zoster in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Herpes Zoster in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Herpes Zoster in UK (2016-2028) *
Table 26: Diagnosed Cases of the Herpes Zoster in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Herpes Zoster in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Herpes Zoster in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Herpes Zoster in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Herpes Zoster in Japan (2016-2028)

List of Figures :

Figure 1: Total Prevalent/Incident Cases of the Herpes Zoster in 7MM
Figure 2: Total Prevalent/Incident Cases of the Herpes Zoster in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Herpes Zoster in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Herpes Zoster in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Herpes Zoster in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Herpes Zoster in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Herpes Zoster in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Herpes Zoster in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Herpes Zoster in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Herpes Zoster in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Herpes Zoster in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Herpes Zoster in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Herpes Zoster in France (2016-2028) *
Figure 14: Diagnosed Cases of the Herpes Zoster in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Herpes Zoster in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Herpes Zoster in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Herpes Zoster in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Herpes Zoster in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Herpes Zoster in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Herpes Zoster in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Herpes Zoster in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Herpes Zoster in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Herpes Zoster in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Herpes Zoster in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Herpes Zoster in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Herpes Zoster in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Herpes Zoster in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Herpes Zoster in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Herpes Zoster in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Herpes Zoster in Japan (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Strategic Venue Partners

RELATED REPORTS

China Autogenous Vaccines Market Report Forecast 2021 2027
China Autogenous Vaccines Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-22Z1818
Sat Oct 02 00:00:00 UTC 2021

Add to Cart

Global Flu Vaccine Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027
Global Flu Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

In 2020 the global Flu Vaccine market size was US 5154 million and it is expected to reach US 7293.3 million by the end of 2027 with a CAGR of 4.8 during 20212027.Global Flu Vaccine Market Size Manufacturers Supply Chain Sales Channel and Clients 20212027.

120 Pages
Type: Report
Code: QYRE-Auto-11H675
Mon Sep 27 00:00:00 UTC 2021

Add to Cart

Global Rabies Vaccine Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027
Global Rabies Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

And in terms of application the largest application is Postexposure Prophylaxis followed by Preexposure Prophylaxis.Market Analysis and Insights Global Rabies Vaccine MarketIn 2020 the global Rabies Vaccine market size was US 877 million and it is expected to reach US 1178 million by the end of 2027 with a CAGR of 4.0 during 20212027.Global Rabies Vaccin.

120 Pages
Type: Report
Code: QYRE-Auto-34M23
Mon Sep 27 00:00:00 UTC 2021

Add to Cart

Global and United States Sulfachloropyridazine Sodium Market Insights Forecast to 2027
Global and United States Sulfachloropyridazine Sodium Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-28M6619
Tue Sep 21 00:00:00 UTC 2021

Add to Cart